Rytary FDA Approval History
FDA Approved: Yes (First approved January 7, 2015)
Brand name: Rytary
Generic name: carbidopa and levodopa
Dosage form: Extended Release Capsules
Company: Impax Laboratories, Inc.
Treatment for: Parkinson's Disease
Rytary (carbidopa and levodopa) is an extended release aromatic amino acid decarboxylation inhibitor and aromatic amino acid combination indicated for the treatment of Parkinson’s disease.
Development timeline for Rytary
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.